Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALAXIES Lung-301: Belrestotug + Dostarlimab vs Pembrolizumab in 1L PD-L1 High Advanced NSCLC
NCT06472076Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 21
01
Overview
A Phase 3 trial of belrestotug in non-small cell lung cancer (NSCLC), sponsored by GSK. Started Jun 2024; status: active, not recruiting.
02
Drugs
belrestotug
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06472076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06472076.